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Abstract The endothelium-derived vasoconstrictor mole-
cule endothelin-1 (ET-1) has been suggested to play a role
in the pathogenesis of Raynaud’s phenomenon (RP) and
systemic sclerosis (SSc). We studied the effect of bosentan
on microvascular structure and function in patients with RP
secondary to limited cutaneous SSc in a mechanistic pilot
study. In this single center, open study, 15 patients with
limited cutaneous SSc were treated with bosentan for
16 weeks with a follow-up period of 4 weeks. Changes in
microvascular structure and function were studied with
assessment of vasodilatory microvascular responses using
laser Doppler fluxmetry combined with iontophoresis,
capillary permeability using fluorescence videomicroscopy,
nailfold capillary microscopy, and serological markers of
endothelial activation. No significant changes were seen in
vasodilator responses to acetylcholine and sodium nitro-
prusside following bosentan treatment. No effect was noted
on capillary permeability during treatment. The number of
nailfold capillaries remained unchanged. The endothelial
activation marker vascular cell adhesion molecule did not
change during treatment, but levels of thrombomodulin
significantly decreased after 12 weeks of treatment.
Bosentan did not induce significant changes in vasodilator
responses, capillary permeability, and capillary density
during treatment, so no evidence was obtained for structural
improvement of microvascular structure and function in this
short-time mechanistic pilot study in patients with lcSSc.
Keywords Bosentan.Endothelialcelldysfunction.
Raynaud’sphenomenon.Systemicsclerosis
Introduction
Raynaud’s phenomenon (RP) is present in more than 95% of
patients with systemic sclerosis (SSc) and is often the first
manifestation of the disease [1, 2]. Endothelial cell dysfunc-
tion, associated with microvascular and macrovascular
abnormalities, is a hallmark of SSc. Signs of endothelial
dysfunction include increased capillary permeability [3, 4],
dysregulation of vascular tone [5–7], and elevated markers of
endothelial cell injury, such as von Willebrand Factor (vWF),
trombomodulin (TM), and soluble vascular adhesion cell
molecule-1(s-VCAM-1) [8–13].
Endothelin-1 (ET-1), a potent vasoconstrictor, has been
suggested to play a role in the pathogenesis of RP and SSc.
Increased levels of ET-1 have been found in patients with
primary and secondary RP [14–19]. Recently, treatment
with bosentan, an ET-1 receptor antagonist, has been shown
to be effective in preventing new digital ulcers in patients
with SSc. Although this effect was seen both in patients
with limited and diffuse cutaneous SS, only the reduction in
patients with diffuse cutanous SSc was statistically signif-
icant. No improvement was seen in symptoms of RP [20].
We found an encouraging improvement in frequency,
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who used bosentan during a period of 16 weeks. The
Raynaud’s Condition Score improved from 4.8±2.6 at
baseline to 2.7±2.1 after 16 weeks of treatment (p=
0.003), and also a significant reduction in total number
and duration of RP attacks was found. However, our study
was not placebo-controlled and no objective improvement
in blood flow was seen [21].
We hypothesized that the beneficial effects of bosentan
in the prevention of digital ulcers and maybe also, as
suggested in our previous study, in SSc-associated RP
could be explained by its effects on microvascular structure
and function in this condition. To test this hypothesis, we
assessed acetylcholine-dependent vasodilatory responses
using laser Doppler fluxmetry with iontophoresis, capillary
permeability using fluorescence videomicroscopy, and
nailfold capillaroscopy and markers of endothelial activa-
tion, at baseline, during treatment, and after discontinuation
of bosentan in patients with SSc and severe RP.
Materials and methods
Patients
Patients from the outpatient clinic with a diagnosis of
Raynaud’s phenomenon secondary to systemic sclerosis
were eligible for the study. Patients had to be at least
18 years old, have a diagnosis of RP as assessed by history
and photoelectric plethysmography during cooling and
rewarming [22], and digital pitting scars and/or ulceration.
Patients had to fulfill the American College of Rheumatology
criteria for systemic sclerosis [23]. Patients were sub-
classified in subsets as defined by LeRoy et al. [1].
Inclusion criteria otherwise included no prior use of
bosentan and the use of a reliable method of contraception
during the study. Patients were not eligible in case of
digital ulcers due to other conditions than SSc, prostanoid
therapy during the last month, sympathectomy of the
upper limb performed within 12 months before study
entry, current smoking or smoking within 4 weeks before
study entry, and any other severe concurrent illness. All
patients had to provide written informed consent. Medi-
cation used for the treatment of SSc was allowed and had
to remain unchanged from 3 months prior to study entry
until the end of the study. Vasodilators, such as calcium
channel antagonists and ketanserin, and other oral medi-
cations for the treatment of RP, such as angiotensin
converting enzyme inhibitors, were allowed and were
continued at the same dosage throughout the study. A total
of 15 patients, all with limited cutaneous SSc, were
recruited. All patients were enrolled during the months
of December and January, except for one, who enrolled in
the study at the beginning of February. No differences in
outdoor temperature were seen until week 12. Baseline
characteristics of the patients are shown in Table 1.T o
compare the results regarding endothelial markers and the
results of laser Doppler flowmetry and iontophoresis, 15
historical age- and sex-matched healthy subjects were
included as controls.
Study design and drug administration
The study was an open study. Ethical approval for the study
was obtained from the Medical Ethical Committee of the
University Medical Center Groningen, The Netherlands.
There was a 2–4 weeks pretreatment period, followed by
16 weeks of treatment and a 4 weeks post-treatment follow-
up. Patients entering the study started with bosentan orally,
62.5 mg bid for 4 weeks, followed by the target dose of
125 mg bid for 12 weeks. Clinical outcome measurements
were recorded at baseline, week 8, week 16, and week 20,
except for the endothelial markers. The laboratory assess-
ments were performed every 4 weeks.
Table 1 Baseline characteristics
Characteristic N=15
Sex No. (%)
Male 1 (7)
Female 14 (93)
Age Year
Median (range) 52 (34–70)
Type of systemic sclerosis No. (%)
Limited cutaneous 15 (100)
Duration of systemic sclerosis Year
Median (range) 4 (1–10)
Duration of Raynaud’s phenomenon Year
Median (range) 10 (2–26)
Immunosuppressive agents No. (%)
Current use
Methotrexate 4 (27)
Former use
Methotrexate 1 (7)
Cyclophosphamide 1 (7)
Azathioprine 1 (7)
Never 8 (53)
Concomitant treatment No. (%)
Calcium-channel blockers 10 (67)
Angiotensin converting enzyme inhibitors 6 (40)
Ketanserin 5 (33)
Statins 2 (13)
Aspirin 6 (40)
Coumarin 2 (13)
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Laser Doppler fluxmetry in combination with iontophoresis
Microvascular endothelium-dependent and endothelium-
independent vasodilation was evaluated with laser Doppler
fluxmetry (LDF) combined with iontophoresis of acetyl-
choline (ACh) and sodium nitroprusside (SNP) as described
previously [24]. Briefly, after a baseline recording of 5 min
at rest (baseline flux), iontophoresis was started by setting
time and current strength based on previously documented
and accepted protocols of multiple fixed doses [25–27].
ACh response was measured at the dorsal side on the
middle phalanx of the third finger of the dominant hand and
SNP on the same site on the nondominant hand. ACh (1%,
Miochol, IOLAB, Bourneville Pharma, The Hague, The
Netherlands) was delivered in seven doses of 0.1 mA using
an anodal current for 20 s, with a 60-s interval between
each dose to achieve a plateau phase, whereas SNP (0.1%,
dissolved in NaCl 0.9%) was delivered in nine doses of
0.2 mA using a cathodal current for 20 s with a 60-s
interval between each dose. The measurements were
performed sequentially. The order of ACh and SNP
delivery was random. The mean flux of the first 5 min
excluding moving artifacts made up the baseline flux. The
plateau flux was defined as the mean flux during the last
2 min of the plateau phase. Absolute increase was defined
as the difference between plateau flux and baseline flux.
Relative increase (vasodilation) was defined as the ratio of
absolute increase and baseline flux. Previous studies found
a day-to-day variation coefficient for ACh-mediated vaso-
dilation of 10–16% and for SNP-mediated vasodilation of
8–16%, in healthy subjects on two occasions [26, 28, 29].
We found comparable variation coefficients, i.e. 16% for
ACh-mediated vasodilation and 18% for SNP-mediated
vasodilation, as determined in ten individuals on two
separate days.
Capillary permeability using fluorescein diffusion
with ‘large field’ fluorescence videodensitometry
Large-window sodium fluorescein (NaF) videodensitome-
try was used to measure skin capillary permeability
according to the method described by Jager et al. [30].
The system consists of an epiillumination microscope
(Olympus BHMJ, Tokyo, Japan) to which a 75 W Xenon
lamp (Osram XBO, Berlin, Germany) is mounted. Emitted
light is filtered using a fluorescence filter set (Olympus
BH2-UDMB, excitation 380–490 nm, barrier 515 nm,
Tokyo, Japan). A 2×3-mm section of the skin of the
medial malleolus of the ankle was visualized (magnification
x100). Immersion oil (Leitz, din 58884, Wetzlar, Germany)
was applied to the skin to increase transparency. A bolus of
NaF solution (0.3 ml of a 15% NaF solution per liter of
estimated blood volume) was injected intravenously. The
epiillumination microscope visualizes the rapid capillary
appearance and the subsequent interstitial leakage of NaF.
Images were recorded by a video camera (Grundig FA-85,
Fürth/Bay, Germany), in which an automatic gain function
was removed, and a S-VHS video recorder. Images were
digitized from tape recording (Data Translation 2862
framegrabber with Iris software) after first appearance of
the dye every second for 20 min. The fluorescence light
intensity (FLI) of each image was computed and expressed
in arbitrary units. One baseline image was digitized to
obtain background FLI, which was subtracted from subse-
quent intensities. Individual maximum intensity (Imax) was
set at 100%. All other intensities were expressed as
percentages of Imax. The average relative intensity over
the first 7 min (Iav(7)) after appearance of the dye was used
as a parameter of NaF transcapillary and interstitial
diffusion. This value showed a day-to-day variability,
expressed as coefficient of variation, of 10% [30]. Dye
arrival time (DAT) was defined as the interval from
injection of the dye until appearance in skin capillaries [31].
Nailfold capillary microscopy
An epiillumination microscope (Olympus BHMJ, Tokyo,
Japan) was used for nailfold capillary microscopy. The
finger of the subject to be examined was placed under the
microscope. All studies were performed in a temperature
controlled room (24°C). The nailfolds of the middle finger
and ringfinger of both hands were examined by widefield
microscopy after acclimatization to room temperature for
15 min. Immersion oil (Leitz, din 58884, Wetzlar,
Germany) was applied to the finger to increase transparency
of the skin. Images were recorded by a video camera
(Grundig FA-85, Fürth/Bay, Germany) and a S-VHS video
recorder. The tapes were evaluated separately by two
observers by using a previously described protocol [32].
Numbers of capillary loops in a defined area of 3 mm in the
middle of the distal row of nailfold capillaries were
counted. The mean score of two observers was given.
Patterns of the visible capillary loops were not scored.
Blood analysis
Serum and plasma samples for measuring endothelial
markers were stored at −20 ºC until analysis. Serum levels
of vascular cell adhesion molecule 1 (s-VCAM-1, R&D
Systems, Abingdon, UK) and thrombomodulin (TM,
Diaclone, Besançon, France) were measured according to
the manufacturer’s instruction. Von Willebrand factor
(vWF) was determined using in-house enzyme-linked
immunosorbent assays as described before [33].
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Values are expressed as mean±SD. In the analysis of the
laser Doppler fluxmetry with iontophoresis the Wilcoxon
signed-rank test was used. NaF leakage curves were
compared by paired t-tests using the area under the curve
(AUC) of the first 500 s. Analysis of the other NaF leakage
parameters, number of nailfold capillaries, and endothelial
markers before, during, and after treatment was performed
with a paired samples t-test. Differences between patients
and age- and sex-matched healthy controls for LDF with
iontophoresis and endothelial markers were assessed by
Student’s t-test or Mann–Whitney U as appropriate. A two-
sided p-value of <0.05 was considered significant.
Results
Laser Doppler fluxmetry in combination with iontophoresis
Compared to age- and sex-matched controls a significantly
decreased ACh-mediated (endothelial-dependent) vasodila-
tion was found in patients before treatment with bosentan
(187±154% (mean±SD) in patients vs 595±448% in con-
trols, p=0.001). SNP-mediated (endothelial-independent)
vasodilation was comparable between SSc patients and
controls (402±413% vs 637±759%, p=0.138).
An increased baseline and plateau flux was seen after
16 weeks of treatment. This improvement was not reflected
in or accompanied by a significant increase in ACh-
mediated vasodilation nor in SNP-mediated vasodilation
(Table 2, Fig. 1). No significant difference was found in
vasodilation during treatment or after discontinuation of
bosentan.
Fluorescence videomicroscopy
The averaged sodium fluorescein leakage curves, obtained
before treatment, and at week 8, week 16, and week 20, are
shown in Fig. 2. The curves for the relative fluorescence
light intensity were comparable before, during, and after
discontinuation of bosentan, although after 8 weeks, when
comparing the area under the curve, a trend towards
increased NaF leakage (p=0.051) was observed (Table 3).
At the same time, a shorter, though not significantly, dye
arrival time was found (p=0.196), suggesting an improve-
ment in skin blood flow. The results of the other capillary
sodium fluorescein leakage parameters are also summarized
in Table 3. The average relative fluorescence light intensity
(Iav(7)) did not significantly change during the study. The
DAT showed a trend to be longer after 16 weeks of
treatment (p=0.075) and was significantly longer at week 20
(p=0.044) when compared to baseline. No difference was
seen in DAT between week 16 and 20. The prolonged DAT
Table 2 Results of laser Doppler flowmetry and iontophoresis
Before treatment (N=15) Week 8 (N=14) Week 16 (N=12) Week 20 (N=9)
ACh-mediated vasodilation
Baseline flux (PU) 32.1±30.5 47.0±37.4 56.4±45.4
* 33.3±38.3
Change from pretreatment values 16.9±42.5 24.7±32.5 −2.42±51.7
Plateau flux (PU) 71.0±46.2 96.8±61.8 123.2±93.8
* 69.2±60.5
Change from pretreatment values 31.9±76.4 55.8±88.1 7.3±67.7
Absolute increase (PU) 39.0±35.1 49.2±38.8 66.8±65.3 35.9±33.3
Change from pretreatment values 15.0±52.2 31.1±60.3 9.8±44.8
ACh-mediated vasodilation (%) 187.3±154.4 142.2±202.6 116.2±84.2 142.8±124.7
Change from pretreatment values −47.0±264.3 −81.0±127.2 −31.3±189.9
SNP-mediated vasodilation
Baseline flux (PU) 23.8±15.8 21.1±14.1 36.8±25.9 51.6±22.9
**
Change from pretreatment values −3.3±22.1 12.1±28.7 22.8±30.6
Plateau flux (PU) 85.2±60.7 56.4±70.0 106.3±102.5 112.1±48.2
Change from pretreatment values −29.9±84.1 13.4±107.3 29.1±74.4
Absolute increase (PU) 61.4±52.9 35.3±61.7 69.5±86.2 57.5±64.4
Change from pretreatment values −25.7±69.2 1.3±94.2 −2.6±84.7
SNP-mediated vasodilation (%) 402.0±413.0 155.0±155.4** 197.8±171.5 145.7±130.0
Change from pretreatment values −244.2±426.4 −235.3±436.7 −151.3±321.2
Values are expressed as mean±standard deviation
ACh acetylcholine, PU arbitrary units of flux, SNP sodium nitroprusside
*p=0.05 compared to before treatment;
**p<0.05 compared to before treatment
828 Clin Rheumatol (2009) 28:825–833at week 20 suggests a reduced skin blood flow, but no
differences were seen in Iav(7) and the curve for relative
fluorescence light intensity as compared to baseline.
Nailfold capillary microscopy
The number of capillaries did not change significantly
during the study period. After 16 weeks of treatment, 10.2±
6.3 capillaries/3 mm were seen compared to 9.7±6.4 capil-
laries/3 mm before treatment with bosentan. Other capil-
laroscopic features were not noted because of low total
number of capillary loops.
Endothelial markers
Concentrations of VCAM-1 and vWF were not increased in
patients with SSc compared to age- and sex-matched
healthy controls (285±84 vs 252±47 ng/ml, p=0.171, and
66±57 vs 119±191 %, p=0.387, respectively). Concen-
trations of TM were increased in patients with SSc
compared to healthy controls (4.8±4.2 vs 3.4±3.2 ng/ml,
p=0.026). VCAM-1 levels did not change during treatment
with bosentan. TM levels significantly decreased after
12 weeks of treatment and remained stably decreased at
the end of the study period and after discontinuation of
bosentan. vWF was significantly increased at week 4 and
20 compared to pre-treatment values, but was not signifi-
cantly different from pre-treatment values at week 8, 12,
and 16 (Table 4).
Discussion
This study is unique in its evaluation of the effects of
bosentan on several outcome parameters of microvascular
structure and function. Bosentan treatment resulted, in these
patients with limited cutaneous SSc and severe RP, as
previously shown in our pilot study, in a significant
improvement of RP attacks [21]. However, bosentan did
not result in any significant changes in microvascular
endothelial-dependent and endothelial-independent vasodi-
lation, capillary permeability, and total number of capillary
loops. The endothelial marker s-VCAM-1 also remained
unchanged, only a decrease in TM was observed during
treatment.
The RAPIDS-1 study found significant improvement in
the prevention of new digital ulcers only in the SSc patients
with a diffuse cutaneous subset [20]. We studied the effects
on microvasculature in patients with a limited cutaneous
subset, so this might explain why we did not find a positive
effect on microvasculature.
Another important finding from this study was the
observation that a reduced microvascular vasodilatory
response to ACh was found in our patients, reflecting
vasodilatory endothelial dysfunction. The endothelium-
independent vasodilatory response to SNP was comparable
to that in healthy controls. This supports not only the
presumed microvascular endothelial dysfunction in SSc
patients, but also the choice of bosentan as an obvious
candidate for the treatment of RP in these patients.
During the last decades, laser Doppler fluxmetry has
been used for evaluating skin microcirculation. LDF
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Fig. 1 a Acetylcholine-mediated and b sodium nitroprusside-
mediated vasodilation during the study period (week 8 and 16 of
bosentan treatment) and 4 weeks after discontinuation of bosentan
(week 20) compared to pre-treatment vasodilation. Symbols represent
the mean; lines represent the 95% confidence interval
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 8 9 10 11 12
time (min)
r
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
 
(
%
)
before treatment
week 8
week 16
week 20
7
Fig. 2 Relative fluorescence light intensity (%) after NaF arrival in
the skin of patients with systemic sclerosis before treatment, at week 8
and16 of bosentan treatment and at week 20 (4 weeks after
discontinuation of bosentan)
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Combining LDF with iontophoresis gives the opportunity
to investigate the endothelial-dependent (ACh) and
endothelial-independent (SNP) vasodilatory flow responses
in the digits or forearm [35]. Impaired microvascular
function or endothelium dysfunction, demonstrated as
decreased endothelium-dependent microvascular reactivity,
has been found in patients with hypertension, diabetes
mellitus, obesity, and preeclampsia [24, 26, 28, 29, 36–38].
Reduced endothelium-dependent vasodilatory responses
were observed in SSc patients [39, 40]. However, some
authors did not find differences in vasodilatory flow
responses between patients with SSc, patients with primary
RP, and healthy control subjects [5, 41]. This might be
explained by methodological differences, like site differ-
ences or a different protocol. In our study we used a
protocol with a fair day-to-day reproducibility, expressed as
coefficient of variation, of about 10–15% [26, 28, 29].
Another possible explanation for the lack of improvement
in endothelial-dependent vasodilation might be a reduced
vasodilatory reserve of the skin microcirculation in patients
with SSc, as previously hypothesized [39].
In contrast to our findings, improvement of endothelial
function in patients with SSc treated with bosentan was
found by Sfikakis et al. [42] as shown by a significant
increase in brachial artery ultrasound-derived flow-
mediated dilation (FMD) following bosentan treatment.
The discrepancy in the treatment effect of bosentan on
endothelial dysfunction might be explained by differences
in vascular bed and in technique used. To study endothelial
function in conduit arteries, ultrasound has been used to
measure FMD of the brachial artery, while LDF is used for
measurement of flow in the microcirculation. Comparison
between these two different non-invasive methods has
revealed conflicting results [43, 44]. However, our study
does also confirms the results found by Sfikakis et al. [42]
since no positive effect of bosentan on peripheral flow
reserve and forearm blood flow using venous occlusion
plethysmography was observed in this study, probably due
to irreversible structural changes since most patients had a
well-established disease. We cannot rule out irreversible
structural vascular abnormalities in our patients, prohibiting
vascular remodeling. Focal stenosis and occlusion in digital
arteries, e.g. the proper digital arteries and ulnar artery, are
common manifestations in SSc patients [45, 46]. Our
results are consistent with a previous report, in which
treatment of bosentan during 24 weeks did not reveal a
significant improvement in endothelial-dependent and
endothelial-independent vasodilation of the digits [47].
In patients with SSc, transcapillary leakage of NaF has
usually been determined at the nailfold capillaries. A major
limitation of this technique in intervention studies has been
the large variability in leakage between visualized capillar-
ies. In previous studies we adapted this technique using
large-window videodensitometry with sodium fluorescein
(NaF) of the forefoot [48] or medial ankle [30, 49]t o
reduce this variability and make it a suitable tool for
intervention studies. Using this technique, our study
showed no improvement during bosentan treatment in total
number of capillaries and in transcapillary leakage. A trend
to increased NaF leakage was seen after 8 weeks of
treatment together with a non-significant decrease in dye
arrival time, suggesting bosentan-related increase in total
skin blood flow. However, no differences in NaF leakage
Table 3 Comparison of the NaF leakage curves before treatment, at week 8 and 16 of bosentan treatment, and at week 20 (4 weeks after
discontinuation of bosentan)
Before treatment Week 8 Week 16 Week 20
Number 14 14 12 11
AUC 2,448±637 2,918±611 2,522±421 2,381±549
Dye arrival time (s) 41±22 32±30 45±23 52±17*
Iav(7) (%) 43.9±12.1 46.0±29.0 44.6±8.6 41.4±11.0
Values are expressed as mean±standard deviation
AUC area under the curve, Iav(7) average relative fluorescence light intensity over the first 7 min
*p<0.05 compared to baseline
Table 4 Endothelial markers before treatment, during treatment and
after discontinuation of bosentan
s-VCAM-1 (ng/ml) TM (ng/ml) vWF (%)
Before treatment 289±83 4.8±4.2 66±57
Week 4 304±110 4.5±2.7 151±86
*
Week 8 292±94 4.3±3.2 101±76
Week 12 291±94 2.1±3.3
* 96±103
Week 16 282±76 2.7±2.4
* 95±93
Week 20 282±92 3.2±3.7
* 147±78
*,**
Values are expressed as mean±standard deviation
s-VCAM-1 serum vascular cellular adhesion molecule-1, TM throm-
bomodulin, vWF von Willebrand factor
*p<0.05 compared to baseline;
**p<0.05 compared to week 16
830 Clin Rheumatol (2009) 28:825–833parameters were present after 16 weeks of treatment. Such
relatively minor changes in permeability, and the increased
DAT at week 20, suggest that these changes are caused by a
decrease in blood flow, since DAT is mainly determined by
skin blood flow. A difference in temperature cannot be held
responsible since room temperature and local skin temper-
ature remained stable.
In our study, endothelial activation markers did not show
consistent changes during treatment with bosentan. We did
find a significant decrease in TM from week 12 till the end
of the study. This result suggests improvement of endothe-
lial dysfunction, i.e. decrease in endothelial cell damage,
especially since baseline values were increased compared to
healthy controls. Otherwise, we did not find a difference in
levelsofs-VCAMandvWFbetweenSScpatientsandhealthy
controls. Soluble adhesion molecules, like s-VCAM-1 are
increased particularly during the early edematous phase of the
disease [11]. The fact that none of our patients had early or
active disease might explain lack of differences, but is also
consistent with a previous report in which bosentan did not
result in changes of ET-1, soluble intercellular adhesion
molecule 1 (ICAM-1) and E-selectin [42]. The observed
increase of vWF at week 4 and 20 could be related to cold
exposition shortly before [50, 51]a ss o m ep a t i e n t sh a db e e n
exposed to cold more than 30 min prior to blood collection,
though skin temperature had returned to normal at this time
point. Levels of s-VCAM and TM were not supposed to be
influenced by cold exposition [51, 52].
Obviously, the major limitation of our study is its
uncontrolled and open design and its relatively short duration.
Also, patients were allowed to continue other vasodilating
agents besides prostanoids. Therefore, a possible effect of
bosentan onvasodilatingresponses and capillary permeability
might be reduced. On the other hand, we found no positive
effect of bosentan on microvascular structure and function.
Since placebo is not supposed to be an effective therapy, the
chance to find a beneficial effect of bosentan in a placebo-
controlledtrial ina short-time study isnot tobeexpected.One
might argue that seasonal variation could have influenced the
resultsofthevascularstudies.Althoughwecannotcompletely
ruleoutaseasonaleffect,outdoortemperatureremainedstable
in all patients until week 12.
In conclusion, the findings of this observational study
indicate that use of the endothelin-1 receptor antagonist does
not induce changes in vasodilator responses, capillary
permeability,andcapillarydensityduringaperiodof16weeks
treatment in patients with lcSSc. As we found a decrease in
TM, some limited improvement of endothelial cell dysfunc-
tion cannot be ruled out. A prospective controlled study,
possibly with a longer follow-up is warranted in order to
examine the efficacy of bosentan on functional and structural
abnormalities in the microvasculature in patients with early
SSc with raised endothelial activation markers.
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